Skip to main content
SpringerLink
Log in

Protective Effects of Salvianolate on Myocardial Injury or Myocardial Infarction after Elective Percutaneous Coronary Intervention in NSTE-ACS Patients: A Randomized Placebo-Controlled Trial

  • Original Article
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objective

To evaluate the protective effects of salvianolate on percutaneous coronary intervention (PCI) related myocardial injury or myocardial infarction after elective PCI in non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients.

Methods

A total of 149 patients with NSTE-ACS who underwent elective PCI were enrolled. The patients were randomly allocated in a 1:1 ratio to the salvianolate group (74 cases) or the control group (75 cases). After exclusion criteria of coronary angiography, 60 patients with PCI therapy remained in the salvianolate group and 68 in the control group. The incidence and the severity of PCI related myocardial injury or myocardial infarction, in addition to major adverse cardiac events (MACEs) during 1 year follow-up after PCI were studied between the two groups. Multivariate logistic regression analysis was used to determine the independent factors for PCI related myocardial injury or myocardial infarction after elective PCI.

Results

Compared with the control group, salvianolate treatment reduced the incidence of PCI related severe myocardial injury or myocardial infarction (11.7% vs. 26.5%, P=0.035). The rate of MACEs or all-cause death within 1 month or 1 year after the procedure was not significantly different between the two groups. Conclusions: Periprocedural treatment with salvianolate reduces the incidence of PCI related severe myocardial injury or myocardial infarction, although it does not influence clinical prognosis. [Chinese clinical trial registry: ChiCTR1800016992]

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2019;40:237–269.

    Article  Google Scholar 

  2. Zeitouni M, Silvain J, Guedeney P, Kerneis M, Yan Y, Overtchouk P, et al. Periprocedural myocardial infarction and injury in elective coronary stenting. Eur Heart J 2018;39:1100–1109.

    Article  CAS  Google Scholar 

  3. Meng C, Zhuo XQ, Xu GH, Liu JL. Protection of salvianolate against atherosclerosis via regulating the inflammation in rats. J Huazhong Univ Sci Technolog Med Sci 2014;34:646–651.

    Article  CAS  Google Scholar 

  4. Liu L, Li J, Zhang Y, Zhang S, Ye J, Wen Z, et al. Salvianolic acid B inhibits platelets as a P2Y12 antagonist and PDE inhibitor: evidence from clinic to laboratory. Thromb Res 2014;134:866–876.

    Article  CAS  Google Scholar 

  5. Han B, Zhang X, Zhang Q, Zhao G, Wei J, Ma S, et al. Protective effects of salvianolate on microvascular flow in a porcine model of myocardial ischaemia and reperfusion. Arch Cardiovasc Dis 2011;104:313–324.

    Article  Google Scholar 

  6. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267–315.

    Article  CAS  Google Scholar 

  7. Li CL, Chen ZL, Chen GC. Effect of Salvianolate on myocardial injury during percutaneous coronary intervention in patients with coronary heart disease and angina pectoris. J Emerg Tradit Chin Med (Chin) 2015;24:1235–1237.

    Google Scholar 

  8. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third universal definition of myocardial infarction. Glob Heart 2012;7:275–295.

    Article  Google Scholar 

  9. Bose D, von Birgelen C, Zhou XY, Schmermund A, Philipp S, Sack S, et al. Impact of atherosclerotic plaque composition on coronary microembolization during percutaneous coronary interventions. Basic Res Cardiol 2008;103:587–597.

    Article  Google Scholar 

  10. Kawamoto T, Okura H, Koyama Y, Toda I, Taguchi H, Tamita K, et al. The relationship between coronary plaque characteristics and small embolic particles during coronary stent implantation. J Am Coll Cardiol 2007;50:1635–1640.

    Article  Google Scholar 

  11. Gasperetti CM, Gonias SL, Gimple LW, Powers ER. Platelet activation during coronary angioplasty in humans. Circulation 1993;88:2728–2734.

    Article  CAS  Google Scholar 

  12. Salloum J, Tharpe C, Vaughan D, Zhao DX. Release and elimination of soluble vasoactive factors during percutaneous coronary intervention of saphenous vein grafts: analysis using the PercuSurge GuardWire distal protection device. J Invasive Cardiol 2005;17:575–579.

    PubMed  Google Scholar 

  13. Mahemuti A, Meneveau N, Seronde MF, Schiele F, Descotes-Genon V, Ecarnot F, et al. Early changes in local hemostasis activation following percutaneous coronary intervention in stable angina patients: a comparison between drug-eluting and bare metal stents. J Thromb Thrombolysis 2009;28:333–341.

    Article  CAS  Google Scholar 

  14. Lansky AJ, Stone GW. Periprocedural myocardial infarction: prevalence, prognosis, and prevention. Circ Cardiovasc Interv 2010;3:602–610.

    Article  Google Scholar 

  15. Jia JY, Lu YL, Li XC, Liu GY, Li SJ, Liu Y, et al. Pharmacokinetics of depside salts from Salvia miltiorrhiza in healthy Chinese volunteers: a randomized, open-label, single-dose study. Curr Ther Res Clin Exp (Chin) 2010;71:260–271.

    Article  Google Scholar 

  16. Huang J, Yuan M, Ma J, Liu R, Dong Z, Zhao G, et al. Protective effects of salvianolate on contrast-induced nephropathy after primary percutaneous coronary intervention: a prospective multicenter randomized controlled trial. Cardiology 2017;138:169–178.

    Article  CAS  Google Scholar 

  17. Li X, Yu C, Sun W, Liu G, Jia J, Wang Y. Simultaneous determination of magnesium lithospermate B, rosmarinic acid, and lithospermic acid in beagle dog serum by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2004;18:2878–2882.

    Article  CAS  Google Scholar 

  18. Fei AH, Cao Q, Chen SY, Wang HR, Wang FL, Pan SM, et al. Salvianolate inhibits reactive oxygen species production in H2O2-treated mouse cardiomyocytes in vitro via the TGFβ pathway. Acta Pharmacol Sin 2013;34:496–500.

    Article  CAS  Google Scholar 

  19. Yue RC, Yang XL, Zhang RY, Liu S, Liu J, Zeng J, et al. The effects and related mechanism of salvianolate on rats with myocardial ischemia-reperfusion injury. Chin J Cardiol (Chin) 2017;45:1072–1077.

    CAS  Google Scholar 

  20. Qi JY, Yu J, Huang DH, Guo LH, Wang L, Huang X, et al. Salvianolate reduces murine myocardial ischemia and reperfusion injury via ERK1/2 signaling pathways in vivo. Chin J Integr Med 2017;23:40–47.

    Article  CAS  Google Scholar 

  21. Chen ZW, Xie YM, Liao X, Wang GQ. Systematic review on safety of salvianolate injection. Chin J Chin Mater Med (Chin) 2016;41:3686–3695.

    Google Scholar 

  22. Cui H, Li XY, Gao XW, Lu X, Wu XP, Wang XF, et al. A prospective randomized multicenter controlled trial on salvianolate for treatment of unstable angina pectoris in a Chinese elderly population. Chin J Integr Med 2019;25:728–735.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiovascular Disease, Huashan Hospital, Fudan University, Shanghai, 200040, China

    Yang Ou, Sheng-jia Sun, Hai-ming Shi, Xin-ping Luo, Yun-zhi Shen, Yu-fei Chen, Wei-hu Fan & Wei Shen

  2. Department of Biostatistics, School of Public Health, Fudan University, Shanghai, 200032, China

    Jian-feng Luo

  3. Medical Department, Shanghai Green Valley Pharmaceutical Co., Ltd., Shanghai, 201203, China

    Hong-ying Liu

Authors
  1. Yang Ou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sheng-jia Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hai-ming Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jian-feng Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xin-ping Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yun-zhi Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yu-fei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wei-hu Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hong-ying Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Wei Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Shen W is the guarantor of this article and contributed to the conception of scope and protocol. Shen W, Luo XP, Fan WH and Shi HM contributed to the design of the study. Ou Y, Sun SJ, Shen W and Shi HM performed the study and collected experiment data. Luo JF performed the statistical analysis. Shen YZ and Chen YF obtained funding for the study and Liu HY was responsible for providing salvianolate solutions used in the study. Ou Y and Sun SJ drafted the initial and final manuscript. All authors have agreed and approved the final manuscript.

Corresponding author

Correspondence to Wei Shen.

Additional information

Conflicts of Interest

Shanghai Green Valley Pharmaceutical Co. Ltd. (Shanghai, China) provided the salvianolate. The Shanghai Green Valley Pharmaceutical Co. Ltd. had no participation or influence on the study design, data collection, statistical analysis, and interpretation of results.

Supported by the National Natural Science Foundation of China (No. 81673701 and No. 81573710)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ou, Y., Sun, Sj., Shi, Hm. et al. Protective Effects of Salvianolate on Myocardial Injury or Myocardial Infarction after Elective Percutaneous Coronary Intervention in NSTE-ACS Patients: A Randomized Placebo-Controlled Trial. Chin. J. Integr. Med. 26, 656–662 (2020). https://doi.org/10.1007/s11655-020-2728-0

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-020-2728-0

Keywords

Search

Navigation